<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30042279</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>09</Month>            <Day>10</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>10</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Print">0385-0684</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>45</Volume>                    <Issue>7</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Jul</Month>                    </PubDate>                </JournalIssue>                <Title>Gan to kagaku ryoho. Cancer &amp; chemotherapy</Title>                <ISOAbbreviation>Gan To Kagaku Ryoho</ISOAbbreviation>            </Journal>            <ArticleTitle>[A Case of Recurrent Breast Cancer with Complete Response to Eribulin Monotherapy after Bevacizumab plus Paclitaxel Combination Therapy].</ArticleTitle>            <Pagination>                <MedlinePgn>1093-1095</MedlinePgn>            </Pagination>            <Abstract>                <AbstractText>A 65-year-old woman underwent mastectomy and dissection of a level I axillary lymph node in January 2002 for left breast cancer. The diagnosis was T1N0M0 scirrhous carcinoma that was estrogen receptor-positive, progesterone receptorpositive, and human epidermal growth factor receptor 2-negative. After 3 years 10 months, during which the patient underwent adjuvant therapy with oral aromatase inhibitors, she developed bilateral multiple lung metastases. These were treated with the anticancer agents anthracycline and taxane. Progressive disease(more and larger lung metastases)was diagnosed in April 2013, and bevacizumab plus paclitaxel combination therapy was started. After completion of 4 courses, a lung abscess appeared, which was conjectured to represent rapid tumor necrosis that had become infected. As several tumors remained solid even after the lung abscess improved, the patient received 18 courses of eribulin monotherapy. Computed tomography in April 2016 revealed only patches of linear or cord-like scarring in both lungs, with no metastatic or recurrent foci. In this case, a patient with recurrent breast cancer responded to the sequential administration of bevacizumab plus paclitaxel combination therapy followed by eribulin monotherapy.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Higashi</LastName>                    <ForeName>Takayuki</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Dept. of Surgery, Okitama Public General Hospital.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ozawa</LastName>                    <ForeName>Koichiro</ForeName>                    <Initials>K</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Takagi</LastName>                    <ForeName>Shinya</ForeName>                    <Initials>S</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Onodera</LastName>                    <ForeName>Yuji</ForeName>                    <Initials>Y</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Yokoyama</LastName>                    <ForeName>Moriyoshi</ForeName>                    <Initials>M</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Mase</LastName>                    <ForeName>Kenzi</ForeName>                    <Initials>K</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Moriya</LastName>                    <ForeName>Toshiyuki</ForeName>                    <Initials>T</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Takeshita</LastName>                    <ForeName>Akiko</ForeName>                    <Initials>A</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Mizutani</LastName>                    <ForeName>Masaomi</ForeName>                    <Initials>M</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Usuba</LastName>                    <ForeName>Osamu</ForeName>                    <Initials>O</Initials>                </Author>            </AuthorList>            <Language>jpn</Language>            <PublicationTypeList>                <PublicationType UI="D002363">Case Reports</PublicationType>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Japan</Country>            <MedlineTA>Gan To Kagaku Ryoho</MedlineTA>            <NlmUniqueID>7810034</NlmUniqueID>            <ISSNLinking>0385-0684</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D005663">Furans</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D007659">Ketones</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>2S9ZZM9Q9V</RegistryNumber>                <NameOfSubstance UI="D000068258">Bevacizumab</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>LR24G6354G</RegistryNumber>                <NameOfSubstance UI="C490954">eribulin</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>P88XT4IS4D</RegistryNumber>                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000068258" MajorTopicYN="N">Bevacizumab</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005663" MajorTopicYN="N">Furans</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D007659" MajorTopicYN="N">Ketones</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30042279</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>